MLYS

Over the past six months, Mineralys Therapeutics' stock price has declined significantly, losing 40.3% over the past year, 35.33% from September 2025 to September 2026, and 37.98% over the last year as of September 2025. The 52-week high for MLYS shares was $47.65, and the 52-week low was $21.46. Key events impacting the stock include the FDA's acceptance of the New Drug Application (NDA) for lorundrostat in March 2026, assigning a PDUFA target date of December 22, 2026, which was a significant regulatory milestone. The company also announced presentations of new lorundrostat data at major scientific sessions in early October 2026. Following its earnings report on August 11, 2026, shares declined by 1.0%, with the next earnings estimated between November 9 and November 13, 2026. Recent SEC filings indicate various share sales, including by the CEO in October 2026, a proposed sale by an officer and director in September 2026, and a fund selling shares in September 2026, alongside reported inducement awards in late September 2026.